Blue Dye 1 vs Butylated Hydroxyanisole: which is worse?

What is Blue Dye 1?

Blue Dye 1 (Brilliant Blue FCF) is a synthetic blue triarylmethane dye derived from petroleum. It produces a brilliant sky-blue color and is highly water-soluble. Unlike the azo dyes (Red 40, Yellow 5/6), Blue 1 belongs to the triarylmethane chemical class.

What is Butylated Hydroxyanisole?

Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum (see also bha entry). It is a mixture of 2-BHA and 3-BHA isomers, used to prevent oxidative rancidity in fats, oils, and fat-containing foods. Chemical formula C11H16O2.

Documented risks

Blue Dye 1: Blue Dye 1 was historically banned in several European countries before EU harmonization permitted it (as E133). EFSA's 2010 comprehensive safety re-evaluation found no evidence of carcinogenicity in standard animal tests. The ADI was set at 6 mg/kg body weight. The most significant documented safety concern for Blue 1 involves intravenous/enteral administration rather than dietary intake. In 2003, the FDA issued a Public Health Advisory warning against using Blue 1 (used as a food coloring agent in enteral nutrition formulas to detect aspiration in critically ill patients) after multiple case reports — including deaths — documented that Blue 1 can be absorbed through damaged intestinal mucosa and cause cardiovascular instability, metabolic acidosis, and death. The FDA advisory specifically warned against this clinical use in intensive care patients. This is a medical use concern, not a dietary intake concern. For healthy consumers eating normally, EFSA found no significant safety concerns at food use levels. Blue 1 was not included in the 2007 Lancet hyperactivity study. However, it falls under the FDA's April 2025 announcement to phase out all petroleum-based synthetic food dyes, reflecting updated policy on the class as a whole rather than specific Blue 1 data. Historically, Blue 1 was banned in multiple European countries due to safety concerns, though EU harmonization later permitted it with E-number labeling requirements. This history suggests precautionary concern even when formal regulatory action was not sustained.

Butylated Hydroxyanisole: IARC classifies BHA as Group 2B (possible human carcinogen) based on forestomach tumor studies in rodents at high doses. The NTP lists it as 'reasonably anticipated to be a human carcinogen.' EFSA's 2012 review found endocrine-disrupting potential. Japan banned it for food use. The FDA permits it at 0.02% of fat content. Concerns about estrogen-receptor interaction have been documented in animal studies. Contact dermatitis from cosmetic use is reported.